G1 Therapeutics Inc Down 19.09% To $1.34 After Earnings Miss

G1 Therapeutics Inc (GTHX) said before open Wednesday that it lost $0.35 per share in quarter three 2023.

On the revenue line, the company reported $12.3 million, missing estimates by $1.9 million.

In the same quarter a year ago, the company lost $0.59 per share on revenue of $23.6 million.

The stock is down 19.09% to $1.34 after the report.

The firm's lower revenue growth to earnings signals that the firm has been able to reduce costs and improve its profit margin overall.

The average recommendation from Wall Street analysts was a Buy which may get revised based on this new data.

InvestorsObserver gives the stock a Bullish Sentiment score at the moment based on recent trading.

G1 Therapeutics Inc has performed a little below average during the past few months. Before the report, G1 Therapeutics Inc received a Long-Term Technical Rank by InvestorsObserver of 27, putting it in the bottom half of stocks. The firm was recently trading at a 52-week low of $1.08 on October 9, 2023 and set a 52-week high on November 1, 2022 at $11.25.

G1 Therapeutics Inc is a commercial-stage biopharmaceutical company. It is engaged in developing novel, small-molecule therapies to target unmet needs in the treatment of cancer. The firm is developing drugs that have the potential to treat most types of cancer, such as cell lung cancer and breast cancer, and designs them to combine - and enhance - the anti-tumor activity of current therapies.